Veradermics, Incorporated

Veradermics, Incorporated FCF per Share

The Free Cash Flow per Share of Veradermics, Incorporated (MANE) as of Oct 21, 2026 is -1.92 USD. In the previous year, Free Cash Flow per Share was -0.12 USD — a change of 1,530.36% (lower).

FCF per Share

-1.92USD

YoY

1,530.36%

Last updated:

Free Cash Flow per Share of Veradermics, Incorporated is 2025 -1.92 USD. Free Cash Flow per Share of Veradermics, Incorporated was 2024 -0.12 USD. It decreases by 1,530.36% lower compared to the previous year.

The Veradermics, Incorporated FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2023
-0.07 USD
Jan 1, 2024
-0.12 USD
Jan 1, 2025
-1.92 USD
The Veradermics, Incorporated FCF per Share history
YEARFCF per ShareYoY
-1.92USD+1,530.36%
-0.12USD+75.34%
-0.07USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veradermics, Incorporated Stock analysis

What does Veradermics, Incorporated do? Veradermics, Incorporated develops novel therapeutics for dermatologic and aesthetic conditions, focusing on treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy, and VDMN, a dissolvable microarray patch technology for immunotherapy of common warts. VDAA targets alopecia areata, while VDMC addresses molluscum contagiosum. These products are used for treating androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in adult and pediatric populations, as well as the broader medical and clinical research community in dermatology. The company's revenue streams are derived from partnerships with healthcare providers and clinical research organizations for product development and clinical trials. These collaborations enable Veradermics to advance its pipeline of treatments, including VDPHL01, VDMN, VDAA, and VDMC, toward regulatory approval and commercialization. The primary buyers of Veradermics' services are healthcare providers and clinical research organizations involved in dermatology, with a focus on adult and pediatric dermatologic care and research. Veradermics operates within the clinical-stage biopharmaceutical sector, targeting dermatologic and aesthetic conditions. Its products are designed for specific conditions such as androgenetic alopecia, common warts, molluscum contagiosum, and alopecia areata, serving both adult and pediatric patient segments. The company's development activities are supported by partnerships with healthcare providers and clinical research organizations, which provide the necessary expertise and infrastructure for clinical trials and product advancement. Veradermics, Incorporated is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veradermics, Incorporated stock

Free Cash Flow per Share of Veradermics, Incorporated is -1.92 USD in 2025.

Free Cash Flow per Share of Veradermics, Incorporated changed from -0.12 USD to -1.92 USD, representing a 1,530.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Veradermics, Incorporated since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Veradermics, Incorporated

All Key Metrics — Veradermics, Incorporated